|
Carol-Ann Ohmstede, PhD, Vice President of Corporate Alliances and Project Planning of the company. Dr. Ohmstede joined Trimeris in 1998, and initially managed the development programs for FUZEON® (T-20, enfuvirtide) and T-1249, while also facilitating collaborations associated with Trimeris development compounds. In 2001, Dr. Ohmstede was promoted to her current position of Vice President of Corporate Alliances and Project Planning. Prior to joining Trimeris, Dr. Ohmstede held various positions of increasing responsibility in the Research and Development Division of Burroughs Wellcome, Inc. and later Glaxo Wellcome. Dr. Ohmstede received her BA degree and PhD in biochemistry from the University of South Florida College of Medicine. | 